Plus Therapeutics Appoints Dr. An van Es-Johansson to Board of Directors
January 02 2020 - 4:15PM
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), today
announced that Dr. An van Es-Johansson has joined the Company’s
Board of Directors to serve as an independent director,
effective January 1, 2020.
Dr. van Es-Johansson currently serves as the Chief Medical
Officer for AlzeCure Pharma, a Swedish pharmaceutical company with
a primary focus on Alzheimer’s disease, where she is responsible
for regulatory, clinical development, clinical operations, and
pharmacovigilance. From 2005-2018, Dr. van Es-Johansson
served in a range of executive roles of increasing responsibility
at Swedish Orphan Biovitrum AB (Sobi), an international specialty
biopharmaceutical company focused on rare diseases. Dr. van
Es-Johansson has leadership experience within large pharmaceutical
and smaller biotechnology companies, including Roche, Eli Lilly,
Active Biotech, and BioStratum. She currently serves on the
Board of Directors at BioInvent International AB, Medivir AB,
Agendia Inc., Savara Inc., and AlzeCure Pharma AB. Dr. van
Es-Johansson received a M.D. from Erasmus University in Rotterdam,
The Netherlands.
"We are excited to welcome Dr. van-Es Johansson to our Board of
Directors. An is an expert in developing orphan drugs that
receive FDA and EMA product approval and achieve commercial
success. Further, she has held global leadership roles across
multiple disciplines of the life sciences industry, including
clinical development, regulatory, and medical affairs, that will
strengthen Plus’ experience in those areas," said Dr. Marc Hedrick,
President and CEO of Plus Therapeutics.
"Plus’ nanotechnology platform and DocePLUS Phase 2-ready orphan
drug product candidate for small cell lung cancer have the
potential to substantially improve the lives of patients battling
cancer and rare diseases,” commented Dr. van Es-Johansson. "In
addition to helping advance DocePLUS toward regulatory approval, I
look forward to supporting the organization in further expanding
and strengthening its pipeline to help more patients in
need." About Plus Therapeutics,
Inc.
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical
company focused on the discovery, development, and manufacturing
scale up of complex and innovative treatments for patients battling
cancer and other life-threatening diseases.
Our proprietary nanotechnology platform is currently centered
around the enhanced delivery of a variety of drugs using novel
liposomal encapsulation technology. Liposomal encapsulation has
been extensively explored and undergone significant technical and
commercial advances since it was first developed. Our platform is
designed to facilitate new delivery approaches and/or formulations
of safe and effective, injectable drugs, potentially enhancing the
safety, efficacy and convenience for patients and healthcare
providers.
Our lead product candidate, DocePLUS, is a protein-stabilized
PEGylated liposomal formulation of docetaxel, for which the process
of preparation is patented. The active pharmaceutical ingredient,
docetaxel, was approved by the U.S. FDA in 1999 and commonly used
for treating cancers of the breast, head, neck, stomach, prostate,
and lung.
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains certain statements that may be
deemed “forward-looking statements” within the meaning of U.S.
securities laws. All statements, other than statements of
historical fact, that address activities, events or developments
that we intend, expect, project, believe or anticipate and similar
expressions or future conditional verbs such as will, should,
would, could or may occur in the future are forward-looking
statements. Such statements are based upon certain assumptions and
assessments made by our management in light of their experience and
their perception of historical trends, current conditions, expected
future developments and other factors they believe to be
appropriate. These statements include, without limitation,
statements about: the Company’s potential to facilitate new
delivery approaches and/or formulations of safe and effective,
injectable drugs, potentially enhancing the safety, efficacy and
convenience for patients and healthcare providers; the Company’s
potential to develop a market leading position; and the potential
for, and timing of, the Company’s submission of a Phase 2 clinical
trial protocol in Small Cell Lung Cancer patients with
platinum-sensitive disease who progressed at least 60 days after
initiation of first-line chemotherapy. The forward-looking
statements included in this press release are subject to a number
of additional material risks and uncertainties, including but not
limited to: the risk that the U.S. FDA does not accept the
Company’s submission of a Phase 2 clinical trial protocol in Small
Cell Lung Cancer patients with platinum-sensitive disease who
progressed at least 60 days after initiation of first-line
chemotherapy; the risk that the Company is not able to successfully
develop product candidates that can leverage the U.S. FDA’s
accelerated regulatory pathways; and the risks described under the
heading “Risk Factors” in the Company’s Securities and Exchange
Commission filings, including in the Company’s annual and quarterly
reports. There may be events in the future that the Company is
unable to predict, or over which it has no control, and its
business, financial condition, results of operations and prospects
may change in the future. The Company assumes no responsibility to
update or revise any forward-looking statements to reflect events,
trends or circumstances after the date they are made unless the
Company has an obligation under U.S. federal securities laws to do
so.
Plus Therapeutics, Inc. Russ Havranek VP
– Marketing, Portfolio Management, Investor Relations Phone:
+1.619.333.4150 Email: ir@plustherapeutics.com
Website: plustherapeutics.com
Plus Therapeutics (NASDAQ:PSTV)
Historical Stock Chart
From Aug 2024 to Sep 2024
Plus Therapeutics (NASDAQ:PSTV)
Historical Stock Chart
From Sep 2023 to Sep 2024